Affibody Progresses Lead Asset To Phase II in Uveitis

IL-17 blocker izokibep targets autoimmune diseases

 
• By Sten Stovall
  
Uveitis Diagnosis
Affibody CEO Says Uveitis Represents Big Commercial Opportunity • Source: Shutterstock

More from Clinical Trials

More from R&D